Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials.

"Declarations Ethics approval and consent to participateEach trial was conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation Guidelines for Good Clinical Practice and approved by the institutional review board and/or independent ethics committee for each study center. All patients provided written informed consent. Consent for publicationNot applicable. Competing interestsJT has received grant/research support from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Genentech, Gilead, Janssen, and Pfizer Inc, has been a consultant/advisory board member for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer Inc, and Sanofi-Genzyme, and is a member of the speakers’ bureau for AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer Inc, and Sanofi-Genzyme. AG has been a consultant for AbbVie, Bristol Myers Squibb, MSD, Novartis, Pfizer Inc, Roche, Servier, UCB, and Xoma. EO has received grant/research support from, and has been a consultant for, AbbVie, Amgen, Celgene, Genentech, Janssen, Pfizer Inc, Regeneron, Sanofi Aventis, UCB, and Vertex Pharmaceuticals. KO has been a member of the speakers’ bureau for AbbVie, Amgen, Bristol Myers Squibb, Crescendo Biosciences, GSK, Pfizer Inc, and UCB. TL, KK, and AE are employees and shareholders of Pfizer Inc. Competing interests JT has received grant/research support from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Genentech, Gilead, Janssen, and Pfizer Inc, has been a consultant/advisory board member for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer Inc, and Sanofi-Genzyme, and is a member of the speakers’ bureau for AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer Inc, and Sanofi-Genzyme. AG has been a consultant for AbbVie, Bristol Myers Squibb, MSD, Novartis, Pfizer Inc, Roche, Servier, UCB, and Xoma. EO has received grant/research support from, and has been a consultant for, AbbVie, Amgen, Celgene, Genentech, Janssen, Pfizer Inc, Regeneron, Sanofi Aventis, UCB, and Vertex Pharmaceuticals. KO has been a member of the speakers’ bureau for AbbVie, Amgen, Bristol Myers Squibb, Crescendo Biosciences, GSK, Pfizer Inc, and UCB. TL, KK, and AE are employees and shareholders of Pfizer Inc."

"Funding This study was sponsored by Pfizer."

"Trial registration NCT00147498/NCT00413660/NCT00550446/NCT00603512/NCT00687193/NCT00976599/NCT01359150/NCT00847613/NCT00814307/NCT00853385/NCT00960440/NCT01039688/NCT00856544."